All News

Writing in The Lancet, researchers discuss disparities in type 1 diabetes care on the 100th anniversary of the discovery of insulin.

Data outline prevalence of COVID-19 breakthrough and long haul infections among patients with rheumatic diseases.

Pfizer has granted a second license to allow its COVID-19 pill to be manufactured and sold in developing countries; a bipartisan group argues against the No Surprises Act; the battle over the 340B discount program continues.

Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.

Anti-CD20 disease-modifying therapies, including rituximab and ocrelizumab, were found to increase the risk of hospitalization and intensive care unit admission in patients with multiple sclerosis (MS) who develop COVID-19, investigators concluded in this new study.

Pain and fear/anxiety were the most common barriers to anti–vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration and diabetic macular edema. Another study found that those conditions had a significant impact on patients’ quality of life and Medicare costs.

The findings showed that between 2009 to 2016, 76% of the 122 patients included in the study were on sick leave a year following their allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Sandoz, Lupin, and Biocon Biologics representatives at the Association for Accessible Medicines (AAM) GRx+Biosims conference said that drug price rebates hinder biosimilar competition.

Prior to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), patients experienced a decrease in health-related quality of life (HRQOL), which was further impaired during and immediately after CAR T therapy.

On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, explains the Health Equity Now initiative and how it shines a light on health disparities.

Researchers have found a second reported case of an immune system potentially curing a person of HIV; US premature birth rates are on the rise in minority groups; most Americans say mental health professionals should be first responders to mental health and suicide situations.

Investigators found that increased heart rate correlated with a decline in the ability for the kidneys to function at 48 weeks after a patient receives a kidney transplant, according to results presented at the 2021 American Heart Association Scientific Sessions.

In both blood and urine samples, patients with systemic lupus erythematosus and renal involvement were found to have higher levels of interleukin-35 compared with patients with systemic lupus erythematosus and no known renal involvement.

Bleeding is a risk with all antiplatelet drugs, whose effects pose a problem when patients need surgery or suffer a traumatic injury. A fast-acting reversal agent would make the drug safer to use.

Chronic obstructive pulmonary disease (COPD) management should take into account patients’ comorbidities, according to a poster presented at the Academy of Managed Care Pharmacy Nexus 2021 meeting. Another poster validated the use of the COPD Treatment Ratio as a measure of exacerbation risk.

Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, addresses the lack of prescribing for sodium-glucose co-transporter 2 (SGLT2) inhibitors during hospitalization for acute heart failure by highlighting their benefits and that they are part of guideline-directed treatment.

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, explains the interim findings of the REVERSE-IT trial that were presented at the 2021 AHA Scientific Sessions.

A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.

The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.

Migraineurs often report auditory symptoms during and in-between attacks.

Lower indirect costs and a lower incidence of serious complications offset the higher cost of the advanced hybrid closed-loop insulin system.

Posters presented at the American Academy of Ophthalmology 2021 annual meeting showed that even patients with mild inflammation with their thyroid eye disease benefitted from teprotumumab and that real-world adherence was consistent with the pivotal clinical trials.

As many as 4% of population-level asthma cases could be attributed to secondhand smoke, the study suggests.

Neck circumference may serve as a suitable alternative to waist circumference when gauging cardiometabolic risks, outside of body mass index and waist circumference, among women with polycystic ovary syndrome (PCOS).

Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the latest in enhanced monofocal intraocular lenses (IOLs).

David Ramsey, MD, PhD, MPH, explains findings from a study on telehealth use among patients with diabetes in Massachusetts.

Findings of a small study conducted in Brazil indicate exercise prescribed to patients with type 1 diabetes (T1D) may need to be tailored based on sex.

A new study provides genetic evidence that increased alcohol intake may be a causal risk factor for geographic atrophy, a type of advanced age-related macular degeneration (AMD), but doctors caution it may be too soon to advise patients about the risk.

For trastuzumab and bevacizumab, biosimilars now represent a high share of administrations, but payer policies still hinder uptake of these products, the Community Oncology Alliance (COA) reports.